The authors say that whilst it has long been suspected that adverse drug reactions are under-reported, this study is the first to show the scale of the problem, using real data from veterinary clinical records.
For the study, researchers looked for electronic heath records within the Small Animal Veterinary Surveillance Network (SAVSNET) which contained “adverse drug reactions” and “side effects” in the free-text clinical narratives.
The results were then analysed to determine the suspected product, the seriousness and expectedness of the event, and whether the event had been reported to the Veterinary Medicines Directorate or Marketing Authorisation Holders.
Of the 827 cases of suspected adverse drug reactions identified out of a total of 10,565 records reviewed, approximately 90% were not reported.
74% were related to dogs and 70% were listed as “expected” (i.e. already listed in the product information).
The clinical severity of the reaction didn’t appear to impact whether it was reported.
Dr Heather Davies, lead author of the study, said: “As adverse drug reaction reporting rate is directly linked to the regulators ability to mitigate safety issues, this paper is a call to arms encouraging all veterinary professionals to report suspected adverse drug reactions and regulators to make reporting quicker and easier.
"It also the highlights the promise that big real-world data sets hold in enhancing drug safety monitoring processes.”
https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13721
Having had a three-month sabbatical working at Fitzpatrick, Jonathan decided to relocate from New Zealand where most recently he'd been Head of the Companion Animal Group at Massey University.
Jonathan said: "My prime passion is working directly with animals and their families in a supportive and exceptional clinical setting. I enjoy pushing boundaries and not accepting the status quo. I want to identify better ways of improving outcomes for patients, and minimising the impact of the disease (or its treatment) on an animal’s quality of life. My sabbatical at Fitzpatrick Referrals exposed me to their tremendous energy and real passion for patient and client care. From the moment the clients walk in the door, I feel there is an embrace that lets people know we truly care and want to do the best for their animal friend. I am looking forward to discovering what we can achieve together. Cancer management is such an important opportunity, with the power to change both animal and human lives positively. The direction and focus of Fitzpatrick Referrals in this area is already incredibly exciting.”
Clinical Director of Oncology and Soft Tissue, Professor Nick Bacon said: "On Jon’s first day of his sabbatical, he jumped right into the team and made an immediate positive impact. He hasn’t looked back. He carries with him such a good energy, which we all absorb and hopefully reflect back. His knowledge of implant design for dealing with defects in the mandible and elsewhere is exceptional and I am looking forward to watching that develop. I am also very pleased that Jon’s wife Sharyn is able to join the team; she is very experienced in the field of advanced imaging in humans, including Fluoroscopy and PET-CT. This is already benefitting our patients as we improve our diagnostic and treatment abilities, and get ready for the future."
Jonathan has active research interests in several clinical areas including soft tissue sarcoma, injection-site sarcoma, endoprosthetics and haemangiosarcoma. He also supports the concept of One Medicine as his PhD research into soft tissue sarcoma, haemangiosarcoma and endoprosthetics has a potential relevance in improving the understanding of treatment paradigms for humans and animals.
Ceva Animal Health has launched Hepatosyl Plus, a development of the liver support supplement for cats and dogs.
Hepatosyl Plus contains the same ingredients as the original product but now also includes Silybin. According to the company, Silybin is the most active isomer of Silybum marianum (milk thistle) which acts as an antioxidant by increasing cellular superoxide dismutase. It joins S-adenosylmethionine (SAMe) and Vitamin E to create a triple antioxidant approach to liver support, helping to neutralise free radicals within the liver. Ceva also says Hepatosyl Plus is the only liver supplement to contain Vitamin K, which is needed by the liver for the production of clotting factors II, VII, IX and X, making it ideally suited for pre- and post-anaesthetic liver support.
Hepatosyl Plus is available in 50mg, 100mg and 200mg sprinkle capsules. For anaesthetic support, Hepatosyl Plus should be administered for one week prior to and following anaesthesia. For long-term use, the capsules should be given once daily for 2-3 months and then reduced to every other day for ongoing maintenance.
For further information, please contact your local CEVA Animal Health territory manager or call 01494 781510.
In the survey of 354 owners, 65% thought their cats get on well with each other. However, 60% reported signs of disharmony, including: chasing (65%), swiping paws (53%), hissing (48%), keeping a distance from one another (31%), fighting and acting aggressively (27%), staring (30%) and sitting in front of resources to block access (25%).
In addition, some of the cats were so stressed that they would often scratch furniture or household items (46%), hide from their housemates (26%), meow excessively (20%) or spray (17%).
Claire Russell, Feliway brand manager at Ceva Animal Health, said: "There is the common misconception that cats need other feline companions, however they are naturally solitary survivors who are more than happy in their own company. Simple environmental changes and using Feliway Friends can help restore harmony between household cats who are displaying signs of multi-cat tension."
Reference
Sarah Gasper, BEVA’S Learning Manager said: "Many of us on the BEVA education team understand exactly what it’s like to return to practice whether after a career break, paternity/maternity or sickness leave. We also understand the specific challenges of moving from mixed into equine practice.
"We have created these courses to help make the transition back to work as smooth as possible. We’ve tried to incorporate everything we wish we had had access to when we returned to practice!"
Reinvigorate your approach to equine practice will be held on 12th March 2019 at Lythe Hill Hotel, Haslemere. The lecture and forum based course will explore the latest advances in internal medicine, orthopaedics, and sports medicine, and how to apply them to develop evidence-based clinical approaches to common and emergency scenarios in practice.
Getting (back) into equine practice will be held on 13th March 2019 at Liphook Equine Hospital, Hampshire. This entirely practical day of CPD will all be about improving the confidence of established equine vets and for vets returning to work following a career break. The course will focus on the practical procedures that an established equine ambulatory vet might be expected to perform on a regular basis. In a new approach to CPD we are trialling a system where delegates can shape part of this unique CPD day for themselves, with an online poll pre-course to select from a choice of practicals.
Both courses will have childcare facilities to help support parents wishing to attend CPD.
BEVA will also be running a course on the fundamentals of sedation, field anaesthesia and castration on 27th and 28th March 2019 at World Horse Welfare, Snetterton, Norfolk. This 'hands-on' course is designed for new or recent graduates or those in mixed practice with varied levels of equine work. It comprises evening lectures on the first day to free up more time for hands-on training on day two. It will cover sedation and field anaesthesia required for common field surgery such as castration, both in theory and in a practical session, with the equine welfare charity venue able to provide a high number of colts for castration work. Nerve blocks and regional anaesthesia for other common procedures will also be covered on cadavers.
For further information on BEVA’s new CPD courses visit www.beva.org.uk/cpd
In 2009, Chiara (pictured right) was the first to be awarded by examination the title of European Veterinary Specialist in Oncology after completing a one-year small animal internship at the University of Glasgow and a three-year residency in internal medicine and oncology at the University of Edinburgh.
Alongside her clinical work, Chiara is an honorary lecturer at the University of Liverpool and a multi-lingual specialist consultant, writer and lecturer at events in the UK and Europe. Her focus is on postgraduate training in small animal oncology and internal medicine and online education of pet owners and animal carers. Chiara is a member of the general and oncology examination committees of the European College of Veterinary Internal Medicine (ECVIM).
She said: "My aim is to provide veterinarians and owners on a daily basis with the most up-to-date information on cancer diagnosis and treatment options so pets can spend more time with their families whilst protecting their quality of life and preventing suffering."
Samuela is a European Specialist in Veterinary Ophthalmology with a special interest in ocular pathology as well as corneal disease and surgery.
She said: "Working at Willows allows me to be part of a talented and passionate team, and a chance to become the best ophthalmologist I can. Willows offers a very high level of patient care, and working here gives me the opportunity for constant scientific and clinical development."
Eurovet Animal Health has announced that it is bringing a veterinary licensed vitamin K1 (phytomenadione) injectable preparation to the UK.
Eurovet says the new preparation, available from the wholesalers by Monday at the latest, will ensure that the previous supply problems of vitamin K1, will be overcome.
According to the company, the intravenous route is the only route to ensure a 100% bioavailability of vitamin K1 almost immediately and in a crisis situation is the best route of treatment. During anticoagulant poisoning, the coagulation factors are present in the body but are not functional. The faster vitamin K1 enters the blood flow, the quicker the coagulation function is restored.
Ruth Vernon, Technical Services Manager for Eurovet said: "We also plan to bring veterinary licenced vitamin K1 tablets to the UK market later in the year, allowing them to be ordered direct from veterinary wholesalers. The future continuity of supply represents a significant improvement on the current situation."
Anticoagulant rodenticide poisoning is the second most common query received by the VPIS. Alexander Campbell, Head of Service at VPIS, said: "The Veterinary Poisons Information Service receives well over 1000 telephone enquiries per annum from UK veterinary professionals seeking advice on how to manage potential and accidental exposures to anticoagulant rodenticides in a variety of animals - mainly pet dogs. Whilst most cases require basic assessment, first-aid and precautionary laboratory tests, an inevitable few develop serious intoxication and need long-term treatment. Vitamin K1 is a mainstay of therapy in these instances, and the availability of licensed veterinary-specific products in the UK is a major advance. Previously, preparations licensed for human use were often the only option when these could be sourced. Anything that ensures ready supply and facilitates speed of therapy for severe cases has to be welcomed."
There are over 500 anticoagulant rodent killing preparations available across Europe. They are available ready to use, as coated cereals, bait blocks, tracking powders, semolina formats or concentrates (which are reserved for professional use). Following cut backs in local council spending on pest control, the National Pest Technicians Association identified in a recent survey* that there is a 'worrying increase in poorly-managed DIY rodent control'.
*The NPTA National Rodent Survey 2009/2010
Novartis Animal Health has announced the launch of Strenzen, an oral water medication for pigs, indicated for the treatment of gastrointestinal infections caused by Escherichia coli, Clostridium perfringens and Salmonella Typhimurium, and for respiratory tract infections caused by Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Strenzen contains contains a combination of amoxicillin trihydrate (500 mg/g) and potassium clavulanate (125 mg/g) in ratio of 4:1. Novartis says it is ideally suited for the treatment of post-weaning infections in pigs.
According to the company, the combination of amoxicillin and clavulanic acid broadens the performance of amoxicillin1,2, especially against resistant strains of bacteria capable of producing ß-lactamase enzymes. Certain bacteria are able to produce ß-lactamase enzymes as a protection mechanism, making the amoxicillin molecule ineffective against them. The clavulanic acid in Strenzen binds to the molecules of the ß-lactamase enzyme, ensuring the amoxicillin remains unaffected and free to attack bacteria. Prof. Dominiek Maes, DVM, MSc, MS, PhD, Dipl. ECVPH, Dipl. ECPHM, from the Porcine Health Management Unit of the Ghent University, Belgium said: "Weaning is a stressful event for piglets and there are several opportunistic diseases that can impact them during this period. The challenge with E. coli and S. suis infections is that in many countries there are currently no commercial vaccines available with proper efficacy. I believe Strenzen can indeed be very helpful in managing those infections which are so prevalent after weaning."
Novartis says Strenzen is rapidly excreted, leading to a withdrawal period of one day, which in turn maximizes production flexibility for pig producers. In addition, the water-soluble formulation of Strenzen ensures that treated pigs get a therapeutic dose even when they stop eating, making it an ideal treatment for sick pigs with compromised appetites.
Recent field trials on infected farms in Spain and the Czech Republic demonstrated that Strenzen-treated pigs give better production performance, better economic returns and require less medical intervention3,4,5. The reduction of the overall amount of antibiotics needed to treat severe post-weaning infections not only saves producers the costs of the labour and the medication, but is also important in regard to the development of resistance in bacteria.
Dr. Ulrich Klein, Global Technical Services Manager, Novartis Animal Health said: "With the launch of Strenzen, Novartis Animal Health demonstrates its commitment to continually broadening our product portfolio to address the specific needs of farmers and food producers. Strenzen has the ideal spectrum for the treatment of post-weaning infections, delivering better productivity results than current therapies for those infections."
References
Idexx has launched Pet Resist (www.petresist.com), an online map of the levels of antibiotic resistance recorded in cats and dogs by the company over the past five years.
The map displays geographical variations in resistance to the top 10 antibiotics used in cats and dogs.
Simon Wootton, UK CAG Marketing Manager from Idexx said: "The ability to select the most appropriate antibiotic prior to testing may increase the effectiveness of treatments and reduce the number of return visits. We believe that this new service will also help prolong the effective life of existing antibiotics at a time when there is considerable pressure on the profession to reduce their use."
Pet Resist shows levels of resistance overlaid on an interactive UK map down to individual postcode areas. You enter the postcode, the antibiotic (amoxicillin, ampicillin, cefaliexn, etc) and the suspected organism (E coli, S aureus, etc), after which you'll be able to see the level of resistance based on historical data from the past five years, and use this to help choose appropriate therapies.
Simon added: "We have used results of MIC tests on over 200,000 samples submitted to Idexx to develop the database upon which the resistance levels are based. The data will be continually updated as we receive more samples at our Wetherby laboratory, further increasing the accuracy and value of the service to vets and their clients."
In current regional anaesthesia procedures two operators are often needed, with an assistant using 'feel' to inject the anaesthetic solution at the required pressure. This, says the company, means anaesthetic solutions can be injected at unsafe pressures. The new device incorporates a safety system that limits injection pressure, to reduce the risk of nerve injury.
Dr. Federico Corletto, Consultant Anaesthetist from Dick White Referrals said: “By turning regional anaesthesia into a one-person procedure, the technology also removes the challenges of communicating with an assistant regarding subjective injective pressure feel, thus removing the unpredictability of an untrained hand.”
Medovate says the use of ultrasound guided regional anaesthesia is becoming more common practice today, with the technique – which can help provide a higher level of visualisation for the practitioner – increasingly seen as a ‘gold standard’.
However, there are limitations and challenges that are not always present in the practice of adult human medicine. Nerve parathesia, for instance, is harder to ascertain in animals. Small animals such as cats also have increased sensitivity to local anaesthetics when compared with other species, necessitating much lower maximum doses be used.1
Brett Hughes, Homecare & Veterinary Business Manager at Vygon UK, said: "The device infuses at 0.5ml/second, and to vets the technology offers a valuable tool that can control injection small intervals at a time. This allows the veterinary practitioner to titrate appropriately to see the anaesthesia spread around a nerve bundle.
"There are a significant number of regional anaesthesia blocks completed in veterinary practice per annum globally, so potentially this NHS developed device could play a major role in the future of veterinary practice."
For more information, visit: https://www.medovate.co.uk/veterinary/safira-for-veterinary-applications and https://www.vygonvet.co.uk/
The company says that despite the development of alternatives to natural bone grafting, such as allografts and synthetic products, autologous bone graft is still considered the standard. However, it has a number of disadvantages, such as donor site morbidities and lameness, limited availability of graft volume (particularly in small size pets) and additional surgical time.
Biocera-Vet is a new bone substitute indicated in surgical procedures where bone grafting is necessary, such as arthrodesis, complex fractures, corrective osteotomy used in correction of limb deformities or as add-on to Tibial Tuberosity Advancement (TTA).
Biocera-Vet is an injectable synthetic self-hardening calcium-phosphate cement combining osteo-inductive, osteo-conductive and osteo-integrative properties designed to support a fast and strong consolidation.
TheraVet says Biocera-Vet also presents an excellent safety profile thanks to its biocompatibility, reduced comorbidities and superior ergonomics which save a significant amount of surgical time.
Dr Olivier Stiévenart, an orthopaedic veterinary surgeon at Surgivet in Belgium said: "Using Biocera-Vet has enabled us to optimise our patient care considerably, by reducing the operating time by at least 30 minutes. The use of an efficient and rapid bone substitute represents a real progress in terms of both operations and the animal’s quality of life".
Julie Schurgers, Chief Commercial Officer of TheraVet, said: "Biocera-Vet is a unique product on the veterinary bone substitute market, combining outstanding bone consolidation properties with an excellent safety profile and superior ergonomics. We are very excited today to announce its commercialisation on the market and are convinced that this innovative product will significantly improve the daily practices of veterinarians, for the well-being of patients and their owners."
The product is now available in Belgium, and will be rolled out in France and the Netherlands shortly, with the rest of Europe following later in 2021 / 2022.
For more information, visit: https://www.thera.vet/en/biocera-vet
MSD Animal Health has announced the launch of Cepralock, a new teat sealant to complement its dry cow intramammary product Cepravin Dry Cow and wider Dairy Herd Health portfolio.
The company says the new product is designed for use at drying off, with or without a dry cow intramammary antibiotic, and provides an important inert barrier in the teat canal to reduce significantly the risk of bacterial infection of the udder during the dry period.
Cepralock is supplied in tubes with the option of short nozzles that are designed to help avoid the risk of teat damage and incorrect administration beyond the teat canal.
The launch is also being accompanied by dry cow therapy training and a support programme for veterinary practitioners and their dairy farmer clients. This will include diagnostics and data analytics, and training will have a significant focus on correct administration and removal of teat sealant after calving, allowing vets to provide adequate reassurances to their clients around product use.
MSD Animal Health technical adviser Martin Behr said: "The dry period is a critical time for vets as they seek to help their clients in the battle to combat mastitis, which remains a significant drain on dairy herd profitability. It provides an ideal opportunity to clear up existing bacterial infections in the udder with the use of intramammary antibiotics, but it is also vital to prevent new infections over the period.
"Cows do have their own natural physical defence against infection in the form of the keratin plug that forms in the teat canal after drying off, but this is not always sufficiently effective. In a recent study it was shown that only 50% of 500 examined quarters had a fully developed keratin plug within 10 days of drying off, whilst 20% of teats remained open into the second half of the dry period. This is significant because the majority of clinical cases of mastitis that occur during the dry period do so within the first three weeks.
"Correct use of a teat sealant at drying off, immediately after the administration of the dry cow intramammary if used, will provide an effective physical barrier for the duration of the dry period, significantly reducing the chances of new infections of the udder."
According to MSD, it is estimated that less than half of dairy cows are currently given a teat sealant at drying off, despite the concept being established for a number of years and numerous farm studies providing strong evidence of their efficacy.
Martin added: "The potential return on investment for dairy farmers of correctly applied teat sealants is clear. A single case of mastitis is estimated to cost between £70 and £250 and the average UK dairy herd suffers somewhere in the region of 50 to 60 cases per 100 cows per lactation. A correctly applied dry cow therapy programme, including the use of teat sealants, will significantly reduce the incidence of clinical mastitis, thereby providing a demonstrable return on investment.
"At MSD Animal Health we are keen to help veterinary practitioners promote best practice in dry cow therapy, including the adoption of the correct protocols and application procedures. Therefore we are supporting the launch of Cepralock with the offer of Continuous Professional Development for veterinary practitioners on all aspects of dry cow therapy, including correct use of teat sealant and its removal after calving."
Cepralock teat sealant is available to veterinary practices in packs of 24 tubes and 120 tubes.
For more information about Cepralock or MSD's Dry Cow Management Support package for vets and farmers, contact your Account Manager.
A group of some of the best-known referral practices in the country has issued a formal response to the recent announcement by pet insurance underwriter RSA that it is building a network of preferred referral practices to direct its clients to.
Whilst RSA has clarified the contents of a letter it sent to practices in the Midlands and North West, and apologised to the profession for the confusion it caused, it has not yet responded to any of the other concerns raised by the profession.
Perhaps chief amongst those is the claim by RSA's Head of Pet Claims, Keith Maxwell, that the company is looking to provide like-for-like treatment at a lower cost from its list of preferred referral practices.
Referral vets from Anderson Moores Veterinary Specialists in Hampshire, Cave Veterinary Specialists in Somerset, Davies Veterinary Specialists in Hertfordshire, Dick White Referrals in Suffolk, North Downs Specialist Referrals in Surrey, The Veterinary Cardiorespiratory Centre in Warwickshire and Willows Veterinary Centre in the West Midlands say that RSA's current list is simply not representative of the RCVS Recognised Specialist expertise and advanced therapies available within the veterinary profession, thereby making it impossible for RSA to offer like-for-like treatment, let alone at a lower cost.
Clive Elwood, Managing Director of Davies Veterinary Specialists in Hertfordshire, speaking on behalf of the practices who have expressed concern about the move, said: "An approach that focuses on cost-cutting rather than quality of patient care and lacks any genuine or objective process to benchmark clinical standards is inappropriate. Many multi-disciplinary centres place enormous value on the importance of Recognised Specialists being involved at every level of care including consultation, anaesthesia and imaging assessment and the proposed restrictions may preclude this level of service in some instances. We understand that balancing high standards of care and affordability for owners and insurance companies is an important issue and we hope insurers will work with all sectors of the profession to find constructive workable long term solutions."
Mike Martin of the Veterinary Cardiorespiratory Centre in Warwickshire added: "Owners buy pet insurance to ensure that they can access the best available expertise when their animals are ill. I don't think any owner wants to have their choice of practice restricted by insurance companies who are primarily concerned with encouraging shortcuts to reduce costs."
The British College of Veterinary Specialists has invited RSA to attend a meeting to discuss issues of concern, but says it hasn't thus far received a reply.
Dilaterol is an oral syrup containing 25 mgs/ml clenbuterol hydrochloride, indicated to treat respiratory disease in horses. It causes intense bronchodilation, inhibits histamine release and increases ciliary mucous clearance. It can be used as a frontline or adjuvant therapy.
Dilaterol is administered via food and comes in a 355 ml bottle with a pump dispenser for easy and accurate dosing.
Emma Jennings, Equine Brand Manager at Dechra said: “We are very pleased to have added Dilaterol to our comprehensive range of equine therapies as it is an established and effective treatment for bronchial conditions.
"It is particularly useful in cases of respiratory allergy, bronchospasm and equine asthma and is already regarded as a valuable tool for veterinary professionals."
Dilaterol will be available to order through wholesalers. For more information, visit www.dechra.co.uk.
Protexin has announced that preliminary data from a clinical trial supports the use of Denamarin® to protect against lomustine (CCNU)-induced hepatotoxicity in dogs.
The study is being performed at the University of California-Davis, Veterinary Medical Teaching Hospital, and the initial results were recently presented at the American College of Veterinary Internal Medicine (ACVIM) Annual Forum. Marketed in the UK by Protexin, Denamarin is the combination of S-adenosylmethionine (SAMe) and silybin.
According to the company, most dogs treated with the chemotherapeutic agent CCNU experience liver enzyme elevation. Elevation of certain liver enzymes such as alanine transferase (ALT) is a key indicator of liver trauma; significant enzyme elevation may lead to a discontinuation, delay, or reduction in chemotherapy. The ongoing clinical trial was designed to evaluate Denamarin as a hepatoprotectant in dogs diagnosed with neoplasia that are undergoing CCNU therapy.
The trial consists of two groups of randomly assigned dogs. Dogs in Group 1 receive Denamarin beginning at the start of CCNU therapy. Group 2 dogs do not receive Denamarin unless they develop a Grade IV hepatotoxicity.
Results of a planned interim analysis completed on the first 30 dogs enrolled revealed that starting Denamarin when CCNU therapy was instituted (Group 1 dogs) appeared to provide hepatoprotection. While the mean post-therapy ALT elevation for Group 1 was 119 IU/L (p=0.1), for Group 2 dogs, the post-therapy ALT level was 815 IU/L (p=0.046). Chemotherapy was altered due to elevated liver enzymes in three Group 2 dogs but only one dog in Group 1.
Janine Barlow, Technical Manager at Protexin said: "We are extremely pleased by the initial findings of this research. The use of Denamarin with chemotherapy looks to help protect liver function allowing for successful completion of therapy and hopefully a longer, happier life for the pet. We look forward to the results of the full study."
Protexin says the SAMe and silybin in Denamarin support and maintain hepatic function by mechanisms including increasing levels of glutathione, the liver's main detoxifying agent; promoting protein synthesis; and stimulating bile flow. Denamarin is useful as part of a polymodal approach to the management of liver health.
Denamarin is available for both dogs and cats in an enteric-coated tablet.
The Stablelab hand-held reader detects and quantifies the biomarker Serum Amyloid A (SAA), an acute phase protein produced by the liver that increases rapidly and dramatically in response to inflammation.
Zoetis says that by measuring SAA, vets can assess the severity of an infection more quickly, often before clinical symptoms start, and are able to monitor the horse’s response over the course of treatment.1
Zoetis vet Wendy Talbot said: “Zoetis is committed to providing vets and horse owners with the most effective health products to better predict, prevent, detect and treat equine disease.
“The Stablelab test kit enables convenient, off-site testing for quick and accurate detection of a reliable indicator of infection in horses.
“Point-of-care testing is one of the fastest-growing areas of diagnostics and this test is rapidly becoming a standard of care in equine practice. SAA testing will help vets to quickly determine an appropriate course of intervention, positively impacting case outcomes.”
For more information, visit: www.stablelab.com. To place an order, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 (option 3).
A survey of almost 1400 ferret owners carried out by the Ferret Education & Research Trust (FERT) and pet food manufacturers James Wellbeloved has revealed that 40% of the UK's ferret owners never take their animals to a vet, with a further 9% saying they visit the vet only occasionally.
In addition, 76% of ferret owners have not had them microchipped, 64% have not bothered with vaccination against distemper and 74% with vaccination against rabies.
Almost three quarters are registered with a vet for emergency treatment, but 26% are not registered at all.
Ian Kearns from FERT said: "This is quite an alarming picture in terms of ferret welfare; however it offers a clear opportunity for vets to address the issue. Ferrets are growing fast in popularity as pets, and it may be that as their role changes they will visit the vet more - but we believe that vets can seize an opportunity by promoting ferret welfare via the waiting room."
The survey also showed that 65% are fed on mixed biscuits and meat. James Wellbeloved Ferret Complete Food was the clear leader, outselling its' nearest rival by almost five times to one. Over half are kept outdoors, and there is a wide choice of bedding material including commercially made washable fabric, straw and paper.
Peter Lancaster, James Wellbeloved marketing director said: "Ferrets are growing in popularity, but because owners sometimes don't do enough research a worrying number are ending up in rescues. Veterinary practices are of course very well-placed to focus on ferret welfare, and we'd urge any vets and vet nurses who want to know more to get in touch with the team at FERT."
10 THINGS YOU NEVER KNEW ABOUT FERRETS...
MsRCVS Sean Cleary and Richard Thomas, and accountant Jane Platt have opened their first practice, Burford Lane Vets in Cheshire, and now plan to open 10 more practices over the next five years, two in Spring 2022
Burford Lane Vets is headed up by Pieter De Villiers MRCVS, who has become an equity owner, supported by a team of nine vets, nurses and receptionists.
Sean said: “Our vets benefit from our many years of clinical, financial, human resources and procurement experience and have the opportunity to add the finishing touches to a state-of-the-art practice, where no expense has been spared on the fit out and equipment.
"Everything from finding a property, negotiating the lease, fitting out the practice and health and safety is taken care of.
"It means our equity partners can enjoy being fantastic vets and reap the financial rewards that brings, and we are here to support the practice and take care of all the administration, procurement, marketing and everything else that goes into running a successful business."
Sean added: “We have benefited from the shift in the industry that saw veterinary groups acquired by large corporate businesses.
"However, this has inadvertently made it difficult for the next generation of vets to follow the traditional route of buying into a practice as they progress from a junior role to partner, as corporate interest has pushed the values of practices to unaffordable levels for most vets.
"We want to bridge that gap and give a leg up to vets who want to be masters of their own destinies, without the difficulty of starting from scratch or having to find a huge initial investment.”
Sean says he thinks there are a great many vets who would like to launch their own practice.
However, starting from scratch is fraught with risk, expense, and complexity.
Sean added: “Our innovative model helps great vets set up in business as leaders of their own practice and our unique offering is already attracting interest from high-calibre individuals.
"We would encourage any colleagues out there who feel they would like to join us in our new venture to get in touch via our website.”
Sean concluded: “The business acumen we have built up over our many years of working in the industry enables us to provide practical support, mentorship and guidance for vets through every step of the process, and that’s something we’re passionate about.
"The directors will be working across all practices to provide support whenever it’s needed. We are in it for the long haul, not just the initial set up stage, and we will become a part of every practice that opens.
“We take a real pride in being the solution to fix the broken practice ownership model and North Star Vets will empower ambitious vets to enjoy a better and more successful future, which in turn will translate into the standard of care our clients enjoy.”
Whilst the decision has been welcomed by the BVA and leading animal charities, it has not been entirely free of controversy. According to various reports, the Press Association has seen a letter from Defra to the Royal Veterinary College in February this year, which said the scientific studies it had commissioned were 'not strong enough to support a ban'.
Talking to the BBC, Ian Gregory, a lobbyist for pet collar manufacturers said that charities had also exaggerated the shock delivered by the collars, which at typically one millijoule is 1000 times less than cattle fencing. He argued that: "The anecdotal problems reported with pet collars can be resolved by product standards rather than by banning a proven technology".
The government has stopped short of banning invisible fencing systems which can keep pets away from roads, saying that the devices are particularly useful for cat owners and animals often respond well to invisible fencing and quickly learn to stay within a boundary without receiving a static pulse.
BVA President John Fishwick said: "As we review the latest evidence on the welfare impact of pulse pet containment fences, we would like to see them covered by a code of practice, as well as the regulation of the sale of these devices and manufacturer’s instructions, to ensure that the potential adverse effects of use are highlighted to animal owners and consumers."
Photo: Shutterstock
Is it right to keep treating an animal just because the technology is available? This is a question that Noel Fitzpatrick, aka the BBC's Bionic Vet, will be addressing at this year's British Veterinary Association (BVA) Congress, in a debate titled 'Treatment too far?' on Friday 24th September at 4pm.
The BVA Congress will take place in the Glasgow Marriott Hotel on 23-25 September 2010 under the theme 'Vets and the Public Good', looking at the role of veterinary surgeons in all aspects of society.
Organisers say that Congress will be a truly Scottish event, led by BVA President Professor Bill Reilly (born and bred in Glasgow and a graduate of Glasgow Vet School) with clinical CPD sessions delivered by Scotland's finest research and academic institutions.
This year also boasts a full non-clinical stream of lectures tackling employment law, management skills, and mental health.
Highlights include:
Vets and the public good: the broader perspective (Wooldridge Memorial Lecture)Professor Stuart Reid, Dean of the Faculty of Veterinary Medicine at the University of Glasgow will deliver the keynote Wooldridge Memorial Lecture. He will consider the extent of the veterinary contribution to society, which extends into areas such as public health, infectious disease control, scientific research, public education, food production, national security, disaster management, care of the environment, and international development. (Fri 24 Sept, 12.15-13.25)
Pets and society: turning a blind eye to abuse?It is nearly a decade since attention began to be drawn to evidence of links between animal abuse and domestic violence towards humans. This session will examine the dilemmas confronting practising vets, asking at what stage should suspicions of abuse be reported and to whom? (Fri 24 Sept, 11.00-12.00)
Four into one must go Following last year's highly popular session, the UK's four CVOs will again come together to debate and discuss current issues in veterinary politics and animal health and welfare, under the chairmanship of BVA President Professor Bill Reilly. (Sat 25 Sept, 9.30-10.30)
Responsibility and cost sharing - where are we now? This session will include a progress report from Rosemary Radcliffe, chair of the independent committee that will be advising the Government on establishing new arrangements in England, and a discussion of what this might mean for practising vets. (Sat 25 Sept, 16.00-17.00)
In addition there will be contentious issue debates on the role of vets in promoting farm animal welfare, the practical difficulties of current dangerous dogs legislation, and the role of vets as experts witnesses in cases of abuse or neglect.
Under the theme of 'public good' there will be a session looking at the role of vets in international development 'Improving the livelihoods of farmers in resource-poor countries', and a session on the zoonotic infections that impact on public health, such as E. Coli and Chlamydia, and what organisations like open farms can do to minimise the risks.
Professor Bill Reilly, President of the BVA, said: "Vets and the public good has been the theme of my presidential term because I believe that the role of vets in all aspects of society should receive more attention.
"Our Congress programme combines the world-renowned expertise of Scotland's academic and research institutes with significant topical issues of debate to capture the widest possible definition of the veterinary contribution to society."
For more information on BVA Congress 2010 (including the full agenda and online registration) visit the BVA website www.bva.co.uk/congress
The awards, comprising academic book vouchers, were presented at the University’s RCVS ceremony after graduation earlier this month.
Jamie Rahman BVSc won the award for the most engaged veterinary student on EMS placement. Feedback about his placement included: 'Exceptional attitude'. 'Contributed actively to good clinical discussion'. 'Intelligent and engaging’. 'Shows true dedication to learning as much as he can whilst in practice, trying to spend as much time with the different specialists as possible'.
Meanwhile, Cheviot Vets in Alnwick won the students' award for outstanding clinical EMS placement 2019. Comments received from students included: ‘I would not be nearly as prepared and ready for practice without the support and training of the team at Cheviot Vets.’ ‘They invested an incredible amount of time into helping me develop my husbandry knowledge and skills.’ ‘Really supportive manner and encouraged me to develop my skills.’
Sarah Heming, Director of Public Affairs and Customer Relations at Zoetis said: "Zoetis has a high focus on supporting the professional advancement of the veterinary profession. We are proud sponsors of the EMS Recognition Awards for Bristol University alongside other initiatives such as the Young Vet of the Year Awards in partnership with the British Veterinary Association.
"The initial stages of a veterinary career are pivotal so helping winning individuals to invest in academic or professional resources to support their continued development in practice can be very beneficial. We would also like to formally thank the winning practices for their invaluable commitment and support."
Feliscratch by Feliway is a synthetic copy of the feline interdigital semiochemical (FIS) naturally produced by cats and Ceva says it is the only product clinically proven to help divert scratching behaviour onto a desired location.
The company says it helps control both vertical and horizontal scratching and helps prevent inappropriate scratching with newly adopted cats or kittens.
The new pheromone is available in a pack of nine single use 5ml pipettes which should be applied on a scratching post to redirect the scratching.
The product attracts cats in three ways: the blue staining mimics the visual message (scratch marks), catnip helps attract the cat to the scratching post and the pheromone directs cat scratching on the surface where the product has been applied. One pack lasts for up to four weeks.
Feliscratch by Feliway can be used alongside Feliway Classic if the owner is experiencing stress-related scratching or alongside Feliway Friends for conflicts in the home.
Claire Russell, pheromone product manager at Ceva Animal Health said: "Scratching is a major problem in cat owning households with many owners experiencing damaged carpets, sofas and other household furniture. Feliscratch by Feliway can help redirect scratching onto a desired location, such as a scratching post, and can be used in conjunction with Feliway Classic and Feliway Friends to help prevent other stress-related behaviours."
Ceva Animal Health has launched a range of marketing materials to support the launch of Feliscratch by Feliway including a pet owner leaflet, posters, wobblers and a digital pack containing social media posts, product pack shots, logo and videos.
For information on Feliway visit www.feliway.com/uk.
The webinar, which is presented by equine internal medicine specialist David Rendle from Rainbow Equine Hospital, challenges some of the current perceptions of worm control in horses and explains why veterinary surgeons need to engage more with horse owners on the topic to ensure a sustainable approach to parasite control.
Supported by Virbac, maker of Equimax and Eraquell horse wormers, the webinar is free to BEVA members at http://www.ebeva.org/webinar74.
Tim was the principal veterinary surgeon at Nine Mile Veterinary Group in Wokingham, Berkshire, from its opening in 1985. He grew the business from one vet and three staff to 16 vets and 60 staff, before selling to CVS in 2007.
Thereupon he became the National Veterinary Director for CVS, supporting the business as it grew from 200 to 1200 vets and supporting individual vets and practices with management advice and clinical practice.
In more recent times Tim has been working with a peripatetic surgery group.
Tim has worked at Guide Dogs before: between 1987 and 2007, he was a Centre Veterinary Advisor at the charity’s now-closed site in Wokingham.
Tim said: “Guide dogs are fantastic to work with – they are good-natured and easy to handle, and the owners always have the best interests of the dog at heart. Plus, you know you are helping more than someone’s pet, a working dog making a real difference to a person’s life. A guide dog needs to be happy and healthy to fulfil its role. It all adds up to a very different flavour of vet work.
“I am looking forward to being back, but in a more central role with more strategic responsibility. The veterinary world has changed so much, even in the last ten years, and it will be good to draw on my experiences to help Guide Dogs traverse that change.
“It’s important that we keep the healthcare of guide dogs at the top of the priorities list; the dogs have always been at the very core of the charity. It’s crucial that we have solid relationships with veterinary practices, to ensure our dogs receive the greatest care at the best value to the charity."
Equip Artervac is indicated for the active immunisation for horses against equine arteritis virus to reduce the clinical signs and shedding of virus in nasal secretions following infection.
Zoetis says it is working hard to resolve the situation and apologises for any convenience caused.
For more information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.